Inovio Pharmaceuticals Inc. (INO)
$1.10
$0.01
(0.92%)
As on 09-Jun-2026 16:00EDT
Market cap
$88 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
14.4
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-3 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-1.1
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-1.5
-
Face value
--
-
Shares outstanding
82,273,237
10 Years Aggregate
CFO
$-1,073.70 Mln
EBITDA
$-1,195.89 Mln
Net Profit
$-1,388.03 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Inovio Pharmaceuticals (INO)
| -36.8 | -24.7 | -36.8 | -51.5 | -45.0 | -59.7 | -38.2 |
|
BSE Sensex
| -12.7 | -4.4 | -6.3 | -10.1 | 5.6 | 7.2 | 10.6 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Inovio Pharmaceuticals (INO)
| -4.9 | -69.8 | -67.3 | -68.7 | -43.6 | 168.2 | -17.5 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Inovio Pharmaceuticals (INO)
|
1.1 | 88.0 | -0.1 | -84.9 | 133,451.5 | -- | -- | 14.4 |
| 73.3 | 10,295.2 | 622.0 | -300.9 | -25.7 | -61.1 | -- | 16.8 | |
| 213.2 | 13,001.6 | 867.5 | 506.6 | -2.8 | -- | 23.9 | 23.8 | |
| 68.5 | 9,704.9 | 105.8 | -829.6 | -715.0 | -- | -- | 60.5 | |
| 53.0 | 13,246.4 | 2,375.5 | 833.4 | 40.8 | 40.7 | 17.5 | 6.8 | |
| 309.8 | 8,873.4 | 417.3 | 225.0 | 42.8 | 18.6 | 40.3 | 6.9 | |
| 476.9 | 11,227.7 | 1,132.5 | -309.4 | -25.5 | -52.9 | -- | 20.9 | |
| 466.8 | 12,973.2 | 2,678.3 | 460.4 | 21.1 | 103.2 | 28.6 | 21.9 | |
| 123.3 | 7,184.9 | 0.0 | -450.1 | -- | -44.6 | -- | 6.3 | |
| 250.3 | 7,081.2 | 0.0 | -326.5 | -- | -37.2 | -- | 5.2 |
Shareholding Pattern
View DetailsAbout Inovio Pharmaceuticals (INO)
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious... diseases. Its DNA medicines platform uses SynCon, to help engineer precisely designed plasmid DNA plasmids, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company's lead product candidate is INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade squamous intraepithelial lesions; INO-3112 for the treatment of HPV-related Oropharyngeal squamous cell carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 2/3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. The company's partners and collaborators ApolloBio Corporation, AstraZeneca, Coherus Biosciences, Defense Advanced Research Projects Agency, HIV Vaccines Trial Network, Kaneka Eurogentec, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter BioLogics, the University of Pennsylvania, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania. Read more
-
CEO, President & Director
Dr. Jacqueline E. Shea Ph.D.
-
CEO, President & Director
Dr. Jacqueline E. Shea Ph.D.
-
Headquarters
Plymouth Meeting, PA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Inovio Pharmaceuticals (INO)
What is the current share price of Inovio Pharmaceuticals Inc (INO) Today?
The share price of Inovio Pharmaceuticals Inc (INO) is $1.10 (NASDAQ) as of 09-Jun-2026 16:00 EDT. Inovio Pharmaceuticals Inc (INO) has given a return of -45% in the last 3 years.
What is the current PB & PE ratio of Inovio Pharmaceuticals Inc (INO)?
Since, TTM earnings of Inovio Pharmaceuticals Inc (INO) is negative, P/E ratio is not available.
The P/B ratio of Inovio Pharmaceuticals Inc (INO) is 14.44 times as on 05-Jun-2026, a 255 premium to its peers’ median range of 4.07 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-9.60
|
33.86
|
|
2024
|
-0.46
|
0.73
|
|
2023
|
-0.09
|
0.10
|
|
2022
|
-0.12
|
0.15
|
|
2021
|
-3.46
|
2.63
|
What is the 52 Week High and Low of Inovio Pharmaceuticals Inc (INO)?
The 52-week high and low of Inovio Pharmaceuticals Inc (INO) are Rs 2.98 and Rs 1.03 as of 10-Jun-2026.
What is the market cap of Inovio Pharmaceuticals Inc (INO)?
Inovio Pharmaceuticals Inc (INO) has a market capitalisation of $ 88 Mln as on 05-Jun-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Inovio Pharmaceuticals Inc (INO)?
Before investing in Inovio Pharmaceuticals Inc (INO), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.